Apellis Historical Cash Flow
| APLS Stock | USD 31.91 1.14 3.70% |
Analysis of Apellis Pharmaceuticals cash flow over time is an excellent tool to project Apellis Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 580.7 M or Other Cashflows From Financing Activities of 9.6 M as it is a great indicator of Apellis Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Apellis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Apellis Pharmaceuticals is a good buy for the upcoming year.
Apellis |
About Apellis Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Apellis balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Apellis's non-liquid assets can be easily converted into cash.
Apellis Pharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Apellis Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Apellis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.At this time, Apellis Pharmaceuticals' Stock Based Compensation is comparatively stable compared to the past year. Begin Period Cash Flow is likely to gain to about 580.7 M in 2024, despite the fact that Free Cash Flow is likely to grow to (565.7 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 6.3M | 61.6M | 26.4M | 15.4M | Depreciation | 1.5M | 1.5M | 1.7M | 1.8M |
Apellis Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Apellis Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Apellis Pharmaceuticals cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 175.7M | 215.1M | 74.7M | (88.7M) | (200.8M) | (190.7M) | |
| Stock Based Compensation | 21.1M | 45.4M | 70.7M | 91.1M | 105.9M | 111.2M | |
| Free Cash Flow | (212.8M) | (165.9M) | (564.2M) | (515.3M) | (595.5M) | (565.7M) | |
| Change In Working Capital | 53.1M | 19.6M | (93.5M) | (15.7M) | (200.2M) | (190.2M) | |
| Begin Period Cash Flow | 176.3M | 352.0M | 567.0M | 641.8M | 553.1M | 580.7M | |
| Other Cashflows From Financing Activities | 307.7M | 369.3M | 11.9M | (14.5M) | 10.1M | 9.6M | |
| Other Non Cash Items | 2.7M | 15.8M | 6.3M | 61.6M | 26.4M | 15.4M | |
| Total Cash From Operating Activities | (211.1M) | (160.5M) | (563.1M) | (513.7M) | (594.7M) | (565.0M) | |
| Net Income | (304.7M) | (344.9M) | (746.4M) | (652.2M) | (528.6M) | (502.2M) | |
| Total Cash From Financing Activities | 388.5M | 692.2M | 392.2M | 365.7M | 394.5M | 264.4M | |
| End Period Cash Flow | 352.0M | 567.0M | 641.8M | 553.1M | 352.3M | 289.7M | |
| Sale Purchase Of Stock | 112.7M | 1.6M | (1.8M) | 4.2M | (11.0M) | (10.5M) | |
| Change To Operating Activities | 54.8M | 19.6M | (77.6M) | 32.6M | 29.4M | 30.8M | |
| Change To Netincome | 37.8M | 148.6M | 274.3M | 152.1M | 174.9M | 183.7M | |
| Change To Liabilities | (1.6M) | (54K) | 10.5M | 18.7M | 21.5M | 22.6M | |
| Issuance Of Capital Stock | 109.6M | 381.4M | 380.4M | 380.1M | 384.4M | 324.0M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.